touchCONGRESS

Current and emerging treatments for chronic myeloid leukemia: What have we learnt from EHA Hybrid Conference 2022?

Access to this content is not permitted for healthcare professionals based in the US and UK.

Back to Home
Haematological Malignancies, Leukaemia Watch Time: 65 mins

touchCONGRESS Current and emerging treatments for chronic myeloid leukemia: What have we learnt from EHA Hybrid Conference 2022?

Watch this two-part activity exploring recent data on current and emerging treatments for CML. Filmed following the EHA Hybrid Conference 2022.

Part 1: Watch Professor Giuseppe Saglio, an expert in CML, review key data from the EHA Hybrid Conference 2022 Watch Now

Part 2: Choose from leading experts who discuss what these data may mean for global and regional practice Select An Interview

  • Part 1: Data Review
Next Chapter
Introduction
New data for emerging treatments in CML
New data for established treatments in CML
Safety of established treatments in CML
Video Player Controls:
 
Leave Feedback
Overview

This activity explores the recent data for current and emerging treatments for chronic myeloid leukemia, filmed following the EHA Hybrid Conference 2022. 

  • Recall the latest data relating to current therapeutic agents for patients with CML
  • Summarize the latest data for investigational therapeutic agents for patients with CML
  • Discuss how the latest data for current and emerging treatments for CML could affect the management of patients in clinical practice
Downloads

View and download resources from this activity to support your learning or share with colleagues

Download Slides
Download Slides

Giuseppe Saglio is emeritus professor of haematology and internal medicine at the University of Turin, Italy. Prof. Saglio has been coordinator of the PhD programme in medicine and experimental therapy at the University of Turin and director of the Department of Clinical and Biological Sciences at the same university. He has published more than 600 peer-reviewed articles in the fields of molecular pathogenesis of haematological diseases, molecularly targeted therapy and molecular characterization of haematological malignancies. In 2017, Prof. Saglio was nominated Knight of the Italian Republic for scientific merits and for his long service to the Italian University.

Professor Giuseppe Saglio discloses: Speaker’s Bureau and Scientific Advisory Board fees from BMS, Incyte, Novartis and Pfizer.

  • Part 2: Expert interviews
Leave Feedback
Professor Giuseppe Saglio
Watch Time: 09:48 University of Turin, Italy

Professor Saglio considers how the latest data on treatments for patients with CML from EHA Hybrid Conference 2022 may influence clinical practice.
 
 
Leave Feedback
Professor François-Xavier Mahon
Watch Time: 09:57 University of Bordeaux, Bordeaux, France

Professor Mahon considers how the latest data on treatments for patients with CML from EHA Hybrid Conference 2022 may influence clinical practice.
 
 
Leave Feedback
Professor Dietger Niederwieser
Watch Time: 12:53 University Hospital, Leipzig, Germany

Professor Niederwieser considers how the latest data on treatments for patients with CML from EHA Hybrid Conference 2022 may influence clinical practice.
 
 
Leave Feedback
Please Select A Video:
Professor Giuseppe Saglio
 University of Turin, Italy Watch Time: 09:48 Translations available:
Watch Video
Professor François-Xavier Mahon
 University of Bordeaux, Bordeaux, France Watch Time: 09:57 Translations available:
Watch Video
Professor Dietger Niederwieser
 University Hospital, Leipzig, Germany Watch Time: 12:53 Translations available:
Watch Video
Leave Feedback
Overview & Learning Objectives
Overview

This activity explores the recent data for current and emerging treatments for chronic myeloid leukemia, filmed following the EHA Hybrid Conference 2022.

Learning Objectives

After watching this activity, participants should be better able to:

  • Recall the latest data relating to current therapeutic agents for patients with CML tesy
  • Summarize the latest data for investigational therapeutic agents for patients with CML
  • Discuss how the latest data for current and emerging treatments for CML could affect the management of patients in clinical practice
Register to touchONCOLOGY for FREE
  • Peer-reviewed journals and expert opinions
  • Interactive CME and e-learning modules
  • Video conference highlights
Register For Free Now
This Activity Is Funded By:

An independent medical education grant from Novartis.
This activity is provided by touchIME.

Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions. The presenting faculty have been advised by touchIME to ensure that they disclose any such references made to unlabelled or unapproved use. No endorsement by touchIME of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in touchIME activities. touchIME accepts no responsibility for errors or omissions.

This content is intended only for healthcare professionals.

Launch date: 21 July 2022.

Feedback Close
Feedback

Please provide feedback for this touchCONGRESS on the following
(scale 1-5, 1 strongly disagree; 5 strongly agree):

* = Mandatory Field

Feedback Close
Feedback

Thank you for your feedback.

Back to Activity
Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
Close Popup